Giving AI Hands on Your Mac

Modern AI can write code and generate images, yet much of its hardware still follows a design rooted in 1945. This episode explores the von Neumann bottleneck: the costly shuttling of information between memory and processors. As AI’s appetite for electricity grows, researchers are rethinking that architecture—bringing computation closer to stored data and borrowing ideas from the brain. Follow the journey through memristors that store values and perform calculations, brain-inspired chips that communicate through electrical spikes, IBM’s NorthPole architecture, and connections that carry data using light. Then enter the world of biological computing, where living neurons interact with silicon and learn to play a simplified version of Pong. Along the way, we explore the engineering hurdles, the promise of more efficient AI on everyday devices, and the demands of keeping a computer’s cells alive. If a machine contains living tissue that can learn and adapt, where do we draw the line between computer and organism?

What if treating sleep apnea started with a bedtime pill and a glass of water? This episode explores AD109, an experimental oral treatment designed to help keep the upper airway open by targeting the nerve signals that control its muscles. Drawing on research originating at Brigham and Women’s Hospital and Harvard Medical School, we unpack why airway anatomy is only part of the story—and how the combination of atomoxetine and aroxybutynin could offer another option for people who struggle with CPAP. We follow the science into the SynAIRgy and LunAIRo clinical trials, examining reductions in breathing interruptions and overnight oxygen deprivation alongside the harder questions: side effects, treatment discontinuation, residual apnea, and whether better numbers translate into feeling more rested. We also explore how this approach differs from weight-loss treatments such as Zepbound and what remains at stake in FDA review. Could the future bring a pill that replaces the mask for some patients—or a combination that makes treatment easier to live with?

What if your morning notifications were a report of everything already handled? Emails drafted, appointments rearranged, and a trip assembled from the Instagram reels you saved and forgot. This episode explores the promise of Meta Muse and the "agentic shift": Al moving from answering questions to carrying out tasks. Drawing on the beta-testing stories and product teardowns discussed in the episode, we examine the vision of a personal chief of staff operating through one continuous conversation-and the new skills involved in deciding what to delegate.

What if your morning notifications were a report of everything already handled? Emails drafted, appointments rearranged, and a trip assembled from the Instagram reels you saved and forgot. This episode explores the promise of Meta Muse and the “agentic shift”: AI moving from answering questions to carrying out tasks. Drawing on the beta-testing stories and product teardowns discussed in the episode, we examine the vision of a personal chief of staff operating through one continuous conversation—and the new skills involved in deciding what to delegate. From bargain hunting and travel planning to AI phone calls and personalized audio briefings, we follow that vision into the details that could make or break it. We unpack the episode’s security claims around confidential computing and tokenized payments, explore persistent goals and the customizable “soul file,” and consider the limits of cloud convenience. Along the way come approval fatigue, frustrated humans on the other end of automated calls, and the pull of Meta’s ecosystem. If an assistant can take care of your daily life, which parts should you still insist on doing yourself?

What if aging cells could recover the instructions that once kept them young? This episode explores David Sinclair’s information theory of aging and the science of partial epigenetic reprogramming—an effort to restore youthful cell function without erasing what makes each cell itself. From experiments in mouse eyes to an early human trial targeting optic nerve disease, we unpack the biological “software” metaphor, the Yamanaka factors, and why the eye has become a testing ground for this ambitious research. Then we examine the distance between a laboratory breakthrough and a treatment you can safely use. We explore the obstacles to whole-body rejuvenation, controversies surrounding resveratrol and NAD+ supplements, and why a younger-looking biomarker doesn’t automatically mean better health. The conversation closes with exercise, sleep, nutrition, and a practical framework for evaluating longevity claims. How can we recognize meaningful progress when the promise of turning back time is also such a powerful sales pitch?